Li et al. (2022) revealed that METTL3 stabilizes ZNF677 mRNA via IGF2BP2- and YTHDF1-dependent m6A modifications, enhancing its translation. Elevated ZNF677 levels transcriptionally repress CDKN3 (cyclin-dependent kinase inhibitor 3), a driver of cell cycle progression, thereby inhibiting ccRCC proliferation and metastasis. This pathway underscores the therapeutic value of METTL3 modulation in restoring tumor suppressor activity (Table 2). This evidence concerns the gene CDKN3 and nonpapillary renal cell carcinoma.